Wedbush Upgrades Fate Therapeutics to Outperform, Raises Price Target to $7
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
Wedbush analyst David Nierengarten upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Outperform and raises the price target from $5 to $7.
Wedbush analyst David Nierengarten upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Outperform and raises the price target from $5 to $7.